The dose-dependent reduction in blood pressure through administration of magnesium. A double blind placebo controlled cross-over study

Am J Hypertens. 1993 Jan;6(1):41-5. doi: 10.1093/ajh/6.1.41.

Abstract

Seventeen patients with a diastolic blood pressure over 90 mm Hg were recruited from a running health screening program to participate in a double blind cross-over study of magnesium supplementation (15 mmol Mg2+/day (Emgesan, Kabi Pharmacia) for 3 weeks, followed by 30 mmol Mg2+/day for another 3 weeks, finishing with 40 mmol Mg2+/day for a final 3 weeks). A significant decrease in the mean systolic blood pressure was recorded from 154.0 +/- 10.7 mm Hg to 146.1 +/- 16.9 mm Hg (P = .031) while the mean diastolic blood pressure decreased from 100.2 +/- 4.2 mm Hg to 92.0 +/- 6.6 mm Hg (P = .0001).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Pressure / drug effects*
  • Diastole
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / physiopathology
  • Magnesium / administration & dosage
  • Magnesium / therapeutic use*
  • Male
  • Middle Aged
  • Systole

Substances

  • Magnesium